Lesions on the back of hands and female gender predispose to stigmatization in patients with psoriasis - 18/04/17
Abstract |
Background |
Psoriasis vulgaris is characterized by disfiguring and stigmatizing skin lesions. The links among lesions distribution, severity, and stigmatization remain unclear.
Objective |
We sought to investigate if the involvement of visible and sensitive areas is linked to stigmatization.
Methods |
In all, 115 patients with psoriasis vulgaris were assessed for disease severity, skin lesions distribution, itch, and stigmatization using the Feelings of Stigmatization Questionnaire. Quality of life was assessed with the Dermatology Life Quality Index and the World Health Organization Quality of Life-BREF.
Results |
The localization of psoriatic lesions on the back of hands was related to higher stigmatization levels (P = .011, total score of the Feelings of Stigmatization Questionnaire), but not the involvement of nails, the palms, the face, or the genital area nor overall disease severity. All patients reported some level of stigmatization, regardless of the localization of lesions and type of psoriasis. Higher levels of stigmatization characterized patients who claimed not to be able to hide their lesions by clothing (P = .025), women (P = .001), and the unemployed (P = .004). Stigmatization was the strongest predictor of quality of life impairment.
Limitations |
Only hospitalized patients were included.
Conclusions |
Psoriatic lesions on the back of hands are debilitating and warrant effective treatment. Special attention should be paid to female patients, who are more sensitive to stigmatization.
Le texte complet de cet article est disponible en PDF.Key words : psoriasis, psychodermatology, quality of life, skin lesions, social rejection, social stigma, stigmatization
Abbreviations used : DLQI, FSQ, HRQoL, PASI, QoL, WHOQOL
Plan
| Funding sources: None. |
|
| Conflicts of interest: None declared. |
Vol 76 - N° 4
P. 648 - avril 2017 Retour au numéro
Article précédent
- The risk of melanoma and hematologic cancers in patients with psoriasis
- Shivani P. Reddy, Kathryn Martires, Jashin J. Wu
- Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept
- Bruce Strober, Alice B. Gottlieb, Bintu Sherif, Patrick Mollon, Isabelle Gilloteau, Lori McLeod, Todd Fox, Margaret Mordin, Ari Gnanasakthy, Charis Papavassilis, Mark G. Lebwohl
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?